

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	May 23, 2023  January 24, 2024

## Prevymis® (letermovir)

**LENGTH OF AUTHORIZATION:** Hematopoietic stem cell transplant - Up to 100 days post-transplantation  
Kidney transplant - Up to 200 days post-transplantation

**REVIEW CRITERIA:**

- Patient must be ≥ 18 years of age.
- Medication must be prescribed for one of the following:
  - Prophylaxis of cytomegalovirus (CMV) infection and disease in a CMV-seropositive recipient (R+) of an allogeneic hematopoietic stem cell transplant (HSCT). *Clinical documentation (i.e., progress notes, labs, discharge summary, etc.) must be provided; OR*
  - Prophylaxis of CMV disease in a kidney transplant recipient at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]). *Clinical documentation (i.e., progress notes, labs, discharge summary, etc.) must be provided.*
- One of the following must be true based on the indication:
  - CMV prophylaxis following hematopoietic stem cell transplant: Medication is being initiated no more than 28 days post-transplant; **OR**
  - CMV prophylaxis following kidney transplant: Medication is being initiated no more than 7 days post-transplant.
- For the injectable formulation, clinical justification explaining why the patient is not a candidate for oral therapy must be provided.
- Medication will not be taken concurrently with any of the following:
  - Pimozide
  - Ergot Alkaloids (i.e., Cafergot, Migranal®, Trudhesa™, etc.)
  - Pitavastatin (Livalo® or Zypitamag®) and simvastatin when co-administered with cyclosporine.
- Treatment is being prescribed by, or in consultation with a provider who specializes in infectious disease, hematology, or organ transplantation.

**Note:** Prevymis® is indicated for CMV prophylaxis in patients at high risk for CMV reactivation following an allogeneic HSCT or kidney transplant, and not for the treatment of an active CMV infection.

**DOSING AND ADMINISTRATION:**

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>
- Available as:
  - Tablet - 240 mg and 480 mg
  - Injection - 240 mg/12 mL (20 mg/mL) and 480 mg/24 mL (20 mg/mL) single-dose vials